ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

AVCRF Avricore Health Inc (QB)

0.069
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Avricore Health Inc (QB) USOTC:AVCRF OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.069 0.07 0.13 0.00 21:00:01

Report of Foreign Issuer (6-k)

21/03/2019 10:06am

Edgar (US Regulatory)


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549  

 


FORM 6-K


 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15b-16 OF

THE SECURITIES EXCHANGE ACT OF 1934


For the month of: December 2016


Commission File Number:   000-51848


 

VANC Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)


N/A

(Translation of Registrant’s name into English)


Suite 810 - 789 West Pender Street Vancouver, BC V6C 1H2 CANADA

 (Address of principal executive office)

 



Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.      Form 20-F xo Form 40-F o

 

Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):    Yes o No x

 

Indicate by check mark if the Registrant is submitting this Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   Yes o No x

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form 6-K is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:    Yes o No x

 



Exhibits


The following exhibits are included in this Form 6-K:

99.1

News Release





SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated:  October 15, 2018

VANC PHARMACEUTICALS INC.

 

 

 

By: /s/ Zula Kropivnitski

 

Zula Kropivnitski

 

Chief Financial Officer




 

 




2


1 Year Avricore Health (QB) Chart

1 Year Avricore Health (QB) Chart

1 Month Avricore Health (QB) Chart

1 Month Avricore Health (QB) Chart

Your Recent History

Delayed Upgrade Clock